Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAvMed Eylea (Aflibercept) ROP Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Aflibercept (Eylea) for Retinopathy of Prematurity — Prior Authorization Coverage Criteria

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and clinical criteria for coverage of Eylea (aflibercept J0177) for treatment of Retinopathy of Prematurity (ROP) in premature infants; intended for AvMed providers requesting outpatient drug approval.

    Policy Summary
    PayerAvMed
    PolicyAflibercept (Eylea) for Retinopathy of Prematurity — Prior Authorization Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit a medical prior authorization request with required clinical criteria and supporting documentation (including ROP staging and birth history) for approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    0.4 mgDose
    10 daysMin interval
    3 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial auth
    ≤32 wkMax GA
    ≤1500 gMax birth wt

    Coverage Criteria for Aflibercept (Eylea) — Retinopathy of Prematurity

    Initial Authorization Criteria

    Covered when ALL of the following are met

    Provider qualifications: Provider is an Ophthalmologist and specializes in the diagnosis of Retinopathy of Prematurity
    Diagnosis: Member has a definitive diagnosis of Retinopathy of Prematurity
    Prematurity criteria (one required): Member is a premature infant with ONE of the following: maximum gestational age at birth ≤ 32 weeks OR birth weight ≤ 1500 ggestational age ≤ 32 weeks; birth weight ≤ 1500 g
    Staging documentation: Provider has submitted infant ROP location & classification according to International Classification ROP (2005) to assess baseline (Zone I/II/III and Stage or AP-ROP)

    Include Zone and Stage (or AP-ROP) as reported on the form

    Not advanced ROP: Infant does NOT have ROP stage 4 or 5

    Reauthorization Criteria

    Reauthorization covered when ALL of the following are met

    Active disease: Member still has the presence of active ROP and requires continued treatment
    Current staging: Provider has submitted current infant ROP location & classification (Zone & Stage) to assess improvement

    Specify improvement status and provide documentation

    Recurrent disease: Member has recurrent ROP and requires re-initiation of treatment

    The policy specifies that treatment for this indication is ONLY applicable to the single-dose vial kit (NDC: 61755-0005-02). Do NOT use the pre-filled syringe for the treatment of Retinopathy of Prematurity (ROP).

    Infants with advanced disease are not eligible for coverage under these criteria. Specifically, the infant must NOT have ROP stage 4 or 5 for approval.

    Billing Codes, NDCs, and Injection Limits

    Requested Drug HCPCSHCPCSCovered
    J0177Aflibercept injectable — Eylea (aflibercept) for Retinopathy of Prematurity (ROP) (Medical)
    Required NDC/FormulationNDCCovered
    NDC: 61755-0005-02Single-dose vial kit — only applicable formulation for ROP; do NOT use the pre-filled syringe for the treatment of ROP
    inv-07: Initial authorization injections — Up to 3 injections per eye over 3 months
    Authorization durationInitial authorization: up to 3 injections per eye over a 3-month period
    Dose per injectionRecommended dosage: 0.4 mg (0.01 mL or 10 microliters) via intravitreal injection
    Minimum intervalMinimum interval between doses in the same eye: at least 10 days
    inv-08: Reauthorization injections — Up to 3 additional injections per eye over 3 months
    Reauthorization durationReauthorization: up to 3 additional injections per eye over a 3-month period
    Documentation requiredProvider must submit current infant ROP location & classification (Zone & Stage) to assess improvement

    Provider Requirements and Submission Guidance

    Prior Authorization

    Prior authorization required for Eylea (J0177)

    Prior authorization is required for Eylea (aflibercept) for Retinopathy of Prematurity (J0177). Complete and submit the medical prior authorization request form with the required clinical criteria and supporting documentation for approval.

    • Submit the completed Medical Prior Authorization/Step-Edit Request form (prescribing physician signature required).
    • Indicate drug requested: Eylea (aflibercept) — ROP (J0177).
    • Check all applicable clinical criteria on the form for initial authorization or reauthorization.
    Step Therapy

    Samples do not meet preauthorization/step criteria

    Use of samples to start therapy does not satisfy step-edit or preauthorization requirements; AvMed will verify prior therapies through pharmacy paid claims or submitted chart notes.

    • Do not rely on samples to meet prior authorization or step therapy edits.

    Background — Retinopathy of Prematurity (ROP)

    Retinopathy of Prematurity (ROP) is a disease of premature infants characterized by abnormal retinal vascular development that can progress through defined zones and stages. Management may require intravitreal anti-VEGF injections such as aflibercept; the form references the International Classification of ROP (2005) for documenting Zone and Stage (including Aggressive Posterior ROP (AP-ROP)). The recommended intravitreal dosage referenced is 0.4 mg per injection, injections may be given bilaterally the same day, and the minimum interval between doses in the same eye is 10 days.

    Definitions and Key Terms

    inv-14: Aggressive Posterior ROP (AP-ROP)
    DefinitionAggressive Posterior Retinopathy of Prematurity (AP-ROP) is a subtype of ROP to be reported with zone/stage when present
    Form reportingAP-ROP has a dedicated field on the authorization form: "Aggressive Posterior Retinopathy of Prematurity (AP-ROP), Zone/Stage"
    Use in assessmentAP-ROP should be included in submitted infant ROP location & classification per International Classification ROP (2005)
    inv-15: Single-dose vial kit — single-dose vial required; pre-filled syringe must not be used
    Required formulationTreatment for this indication is ONLY applicable to the single-dose vial kit (NDC: 61755-0005-02)
    Pre-filled syringe restrictionDo NOT use the pre-filled syringe for the treatment of ROP
    Policy Summary
    PayerAvMed
    PolicyAflibercept (Eylea) for Retinopathy of Prematurity — Prior Authorization Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit a medical prior authorization request with required clinical criteria and supporting documentation (including ROP staging and birth history) for approval.
    SourceLink
    On This Page
    Coverage Criteria for Aflibercept (Eylea) — Retinopathy of PrematurityBilling Codes, NDCs, and Injection LimitsProvider Requirements and Submission GuidanceBackground — Retinopathy of Prematurity (ROP)Definitions and Key Terms
    Indication for re-initiationReauthorization supported if member has recurrent ROP requiring re-initiation of treatment
  1. Provide documentation of prior treatments (pharmacy claims or chart notes) when applicable.
  2. Documentation Required

    Submit supporting clinical documentation

    Provider must submit documentation supporting each checked clinical criterion on the form; include lab results, diagnostic tests, and chart notes. For ROP, include infant ophthalmology notes and ROP imaging and the infant ROP location & classification per International Classification of ROP (2005) where available.

    • Include infant ROP location & classification (Zone and Stage or AP-ROP) and any relevant imaging.
    • Attach lab results, diagnostic reports, and chart notes that substantiate each checked criterion.
    Denial Risk

    Incomplete or illegible submissions risk delay or denial

    Authorization may be delayed or denied if the submission is incomplete, incorrect, or illegible; missing required information such as diagnosis, gestational age, or weight can prevent approval.

    • Ensure all required fields (diagnosis, ICD code if applicable, weight and date weight obtained, dosing schedule) are completed and legible.
    • Incomplete or missing documentation (lab results, diagnostics, chart notes) may result in denial or processing delays.
    Relevant dosing noteRecommended intravitreal dosage and formulation details are specified on the form (0.4 mg per injection)